- Efficacy of the pocket-creation method with a traction device in endoscopic submucosal dissection for residual or recurrent colorectal lesions
-
Ide D, Ohya TR, Ishioka M, Enomoto Y, Nakao E, Mitsuyoshi Y, Tokura J, Suzuki K, Yakabi S, Yasue C, Chino A, Igarashi M, Nakashima A, Saruta M, Saito S, Fujisaki J
- KMID: 2533305
- Clin Endosc.
- 2022 Sep;55(5):655-664.
- doi: 10.5946/ce.2022.009
Background/Aims: Endoscopic submucosal dissection (ESD) for residual or recurrent colorectal lesions after incomplete resection is challenging because of severe fibrosis. This study aimed to compare the efficacy of the pocket-creation... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
-
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M
- KMID: 2539010
- Intest Res.
- 2023 Jan;21(1):110-125.
- doi: 10.5217/ir.2021.00143
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
-
Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick K, Cataldi F, Watanabe M, Hibi T
- KMID: 2501366
- Intest Res.
- 2020 Jan;18(1):45-55.
- doi: 10.5217/ir.2019.00039
Background/Aims: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high... -
- CITED
-
- Close
- SHARE
-
- Close
